Skip to main content
    F

    Fulcrum Therapeutics Inc (FULC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.71
    -0.06 (-1.59%)

    Market Cap: $287.96M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Fulcrum Therapeutics Inc (FULC) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Fulcrum Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025, down 100.0% from the year before. That year, net income was -$74.88M, operating cash flow was -$60.06M and free cash flow was -$60.38M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$10.94M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $84.77M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0-100.0%N/AN/AN/A
    Dec 2024$80.00M+2752.0%100.0%-27.4%-12.2%
    Dec 2023$2.81M-55.8%100.0%-3945.2%-3470.1%
    Dec 2022$6.34M-66.9%100.0%-1774.9%-1732.4%
    Dec 2021$19.16M+117.2%100.0%-423.0%-421.9%
    Dec 2020$8.82MN/A100.0%-811.6%-802.7%
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$0$80.00M$2.81M$6.34M$19.16M$8.82M$0$0$0
    Cost of revenue$0$0$0$0$0$0$0$0$715.00K
    Gross profit$0$80.00M$2.81M$6.34M$19.16M$8.82M$0$0-$715.00K
    Research and development$56.10M$63.39M$71.80M$76.78M$69.70M$59.04M$71.07M$25.18M$18.49M
    Operating income-$84.77M-$21.90M-$110.66M-$112.56M-$81.05M-$71.61M-$84.22M-$33.50M-$22.99M
    Net income-$74.88M-$9.72M-$97.33M-$109.87M-$80.85M-$70.82M-$82.68M-$32.59M-$22.96M
    EBITDAN/AN/AN/A-$110.00M-$77.87M-$69.30M-$82.16M-$31.76M-$22.28M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$0$0$80.00M$0$871.00K
    Gross profit$0$0$0$300.00K$0$0$0-$369.00K$0$80.00M$0$871.00K
    Operating income-$13.86M-$29.31M-$22.19M-$22.69M-$21.86M-$19.82M-$20.40M-$19.43M-$25.13M$52.49M-$29.83M-$27.99M
    Net income-$10.94M-$26.18M-$18.89M-$20.33M-$19.59M-$17.30M-$17.66M-$16.57M-$21.70M$55.41M-$26.87M-$24.76M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.40M by $195.13M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$366.28M$260.72M$257.69M$226.69M$235.00M$129.58M$110.44M$85.77M$4.34M
    Current assets$357.48M$249.92M$242.20M$207.52M$226.00M$119.51M$100.08M$74.09M$1.34M
    Cash and equivalents$197.53M$58.21M$25.56M$35.10M$35.41M$57.05M$96.71M$72.80M$407.00K
    Total liabilities$17.28M$17.68M$22.50M$27.74M$23.46M$34.40M$23.29M$9.77M$3.02M
    Short-term debt$2.40M$2.19M$2.19M$2.60M$9.63M$17.00K$50.00K$46.00K$0
    Shareholder equity$349.00M$243.03M$235.19M$198.94M$211.54M$95.18M$87.15M-$63.67M$1.32M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$310.81M$323.95M$346.77M$366.28M$214.86M$228.84M$242.65M$260.72M$279.01M$294.26M$232.59M$257.69M
    Total liabilities$8.78M$13.26M$13.47M$17.28M$16.49M$14.46M$14.16M$17.68M$21.72M$20.47M$19.00M$22.50M
    Cash and equivalents$116.41M$48.47M$50.26M$197.53M$47.08M$42.59M$42.18M$58.21M$72.63M$86.70M$39.95M$25.56M
    Shareholder equity$302.03M$310.70M$333.30M$349.00M$198.37M$214.38M$228.49M$243.03M$257.29M$273.79M$213.59M$235.19M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$60.06M-$2.22M-$90.97M-$97.05M-$78.48M-$53.66M-$39.48M-$22.56M-$20.07M
    Capital expenditures$314.00K$278.00K$508.00K$1.96M$1.71M$1.34M$853.00K$9.15M$1.91M
    Free cash flow-$60.38M-$2.50M-$91.47M-$99.01M-$80.19M-$55.00M-$40.34M-$31.72M-$21.98M
    Dividends paidN/AN/AN/AN/AN/A$68.52MN/A$0$0
    Investing cash flow$30.72M$32.23M-$36.69M$12.41M-$129.67M-$57.14M-$944.00K-$8.98M-$1.91M
    Financing cash flow$168.67M$2.75M$118.12M$84.32M$186.51M$71.13M$64.34M$105.03M$17.66M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$13.38M-$16.04M-$18.75M-$16.80M-$14.19M-$13.82M-$15.26M-$16.76M-$19.07M$58.90M-$25.28M-$23.16M
    Capital expendituresN/A$108.00K$8.00K$159.00K$90.00K$65.00K$0$231.00K$19.00K$19.00K$28.00K$77.00K
    Free cash flowN/A-$16.15M-$18.76M-$16.96M-$14.28M-$13.88M-$15.26M-$16.99M-$19.09M$58.88M-$25.31M-$23.23M
    Last 12 quarters

    Frequently Asked Questions About FULC

    What is Fulcrum Therapeutics' annual revenue?

    Fulcrum Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    How fast is Fulcrum Therapeutics' revenue growing?

    Revenue was down 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Fulcrum Therapeutics profitable?

    No. Fulcrum Therapeutics reported net income of -$74.88M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does FULC generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$60.06M minus capital expenditures of $314.00K produced free cash flow of -$60.38M.

    How much debt does Fulcrum Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.40M and cash and equivalents of $197.53M.